Possible induction of graft-versus-leukemia effect against a leukemia refractory to antileukemia response in ordinary MHC-compatible, allogeneic bone marrow transplantation

Transplantation

Volumn 65, Issue 7, 1998, Pages 893-898

  Aizawa, Shiro ^a   Kamisaku, Hitoko ^a   Sado, Toshihiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNE RESPONSE; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED C3H; T-LYMPHOCYTE SUBSETS;

EID: 0032522365     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199804150-00006     Document Type: Article

References (36)

1. Borani M. Graft versus leukemia in bone marrow transplantation. Blut 1988; 57: 57.
2. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185.
3. Horowitz M, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
4. Sullivan KM, Fefer A, Witherspoon R, et al. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Prog Clin Biol Res 1987; 244: 391.
5. Fefer A, Sullivan KM, Weiden P, et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res 1987; 244: 401.
6. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195.
7. Kolb HJ, Mittermuller J, Clemm Ch, et al. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462.
8. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261.
9. Kolb HJ, Schattenberg A, Goldmann JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86: 204
10. Aizawa S, Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991; 52: 885.
11. Aizawa S, Sado T, Kamisaku H, Nemoto K, Yoshida K. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias. Bone Marrow Transplant 1994; 13: 109.
12. Aizawa S, Kamisaku H, Sado T. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-disease. Bone Marrow Transplant 1995; 16: 603.
13. Seki M, Yoshida K, Nishimura M, Nemoto K. Radiation-induced myeloid leukemia in C3H/He mice and the effect of prednisolone acetate on leukemogenesis. Radiat Res 1991; 127: 146.
14. Kuriu A, Fujita J, Kanakura Y, Yonezawa T, Yoshida K, Kitamura Y. Acceleration of a murine T-cell leukemia associated with loss of interleukin-3 producing activity. Leuk Res 1989; 13: 77.
15. Aizawa S, Sado E, Kubo E. H-2 restriction specificity of T cells from H-2 incompatible radiation bone marrow chimeras: further evidence for the absence of crucial influence of the host/ thymus environment on the generation of H-2 restricted TNP-specific T lymphocyte precursors. Cell Immunol 1984; 83: 360.
16. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51.
17. Weiss L, Weigensberg M, Morecki S, et al. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother 1990; 31: 236.
18. Okunewick JP, Kociban DL, Machen LL, Buffo MJ. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplant 1991; 8: 445.
19. Hercend TH, Takvorian T, Nowill A, et al. Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722.
20. Drbynski WR, Piaskowski V, Ash RC, et al. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow. Transplantation 1990; 50: 625.
21. Mackinnon S, Hows JM, Goldman JM. Induction of in vivo graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990; 76: 2037.
22. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003.
23. Piontek, GE, Taniguchi K, Ljunggren HG, et al. Yac-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol 1985; 135: 4281.
24. Kaufman DS, Schoon RA, Leibson PJ. MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition. J Immunol 1993; 150: 1429.
25. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377.
26. Nimer S, Giorgi J, Gajewski J, et al. Selective depletion of CD8-positive cells for prevention of graft-versus-host disease following bone marrow transplantation: a randomized controlled trial. Transplantation 1994; 57: 82.
27. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337.
28. van Lochem E, De-Gast B, Coulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant. 1992; 10: 181.
29. LeFever AV, Truitt RL, Shih CC. Reactivity of in-vitro-expanded alloimmune cytotoxic T lymphocytes and Qa-1-specific cytotoxic T lymphocytes against AKR leukemia in vivo. Transplantation 1985; 40: 531.
30. Dolstra H, Fredrix H, Preijers F, et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997; 158: 560.
31. Wallny H-J, Rammensee H-G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343: 275.
32. Elliott T, Townsend A, Cerundolo V. Naturally processed peptides. Nature 1990; 348: 195.
33. Falk K, Rotzschke O, Rammensee H-G. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 1990; 348: 248.
34. Steinmuller D, Wachtel SS. Transplantation biology and immunogenetics of murine skin-specific (SK) alloantigens. Transplant Proc 1980; 12: 100.
35. Rosengard BR, Kortz EO, Ojikutu CA, et al. The failure of skin grafting to break tolerance to class I-disparate renal allografts in miniature swine despite inducing marked anti-donor cellular immunity. Transplantation 1991; 52: 1044.
36. Lorenz R, Allen PM. Processing and presentation of self-proteins. Immunol Rev 1988; 106: 115.